World Journal of Pharmaceutical Science and Research
www.wjpsronline.com
Review Article
ISSN: 2583-6579
SJIF Impact Factor: 6.916
Year - 2026
Volume: 5; Issue: 8
Page: 568-584

# ARTIFICIAL INTELLIGENCE AND NANOPARTICLES IN SMART DRUG DELIVERY: EMERGING TRENDS AND FUTURE DIRECTIONS

**Asthaa Navlani[1], Anvesh Davak*[2], Sandhya Mourya[2], Parash Tomar[1], Dr. Navneet Garud[1]**

[1]School of Studies in Pharmaceutical Sciences, Jiwaji University, Gwalior 474011.

[2]Jain College, Gwalior 474001.

*Article Received: 22 June 2026 || Article Revised: 13 July 2026 || Article Accepted: 03 July 2026*

***Corresponding Author: Anvesh Davak**
Jain College, Gwalior 474001.
**DOI:** https://doi.org/10.5281/zenodo.21825068

**How to cite this Article:** Asthaa Navlani, Anvesh Davak, Sandhya Mourya, Parash Tomar, Dr. Navneet Garud (2026) ARTIFICIAL INTELLIGENCE AND NANOPARTICLES IN SMART DRUG DELIVERY: EMERGING TRENDS AND FUTURE DIRECTIONS. World Journal of Pharmaceutical Science and Research, 5(8), 568-584.



## ABSTRACT

By facilitating the creation of intelligent nanocarriers with improved precision, safety, and therapeutic efficacy, artificial intelligence (AI) and nanotechnology are revolutionizing the field of smart medication delivery. The clinical performance of conventional drug delivery systems is frequently limited by their poor bioavailability, non-specific tissue distribution, quick drug breakdown, and systemic toxicity. A promising approach to overcoming these obstacles through predictive formulation design, physicochemical property optimization, and customized therapeutic interventions is provided by the convergence of AI with nanoparticle-based delivery systems. The design and optimization of various nanoparticle systems, such as lipid-based nanoparticles, polymeric nanoparticles, liposomes, niosomes, dendrimers, hydrogels, and inorganic nanocarriers for targeted and stimuli-responsive drug delivery, are all rigorously examined in this review. Additionally, the design of nanoparticles, drug loading optimization, release kinetics prediction, toxicity evaluation, and precision medicine are examined in relation to contemporary developments in machine learning, deep learning, and explainable artificial intelligence. While addressing present issues with regulatory approval, data quality, algorithm transparency, large-scale manufacturing, and clinical translation, the review also highlights new biomedical applications in cancer therapy, neurological disorders, infectious diseases, gene therapy, and vaccine delivery. In order to expedite the development of next-generation nanomedicines, future prospects highlight the integration of digital twins, autonomous formulation platforms, multimodal biological datasets, and explainable AI. A paradigm shift toward intelligent, patient-centric medication delivery systems that can enhance therapeutic results and advance precision healthcare is represented by the intersection of AI and nanotechnology.

**KEYWORDS:** Artificial Intelligence, Smart Drug Delivery, Nanoparticles, Nanomedicine, Machine Learning, Targeted Drug Delivery, Precision Medicine, Controlled Drug Release, Nanocarriers, Personalized Medicine.

## INTRODUCTION

In contemporary drug delivery, nanomaterials have appeared as revolutionary platforms that present special chances to get around the drawbacks of traditional treatments. Traditional drug formulations frequently have poor solubility, low stability, rapid clearance, and lack of tissue selectivity, all of which reduce therapeutic efficacy and increase systemic side effects. However, it is possible to carefully control the physical properties of nanomaterials, including their size, shape, surface charge, porosity, and surface functionalization. These features enable better solubility and circulation time, controlled medication release, enhanced cellular absorption, and accurate administration to diseased tissues or organs. For instance, liposomes, polymeric nanoparticles, dendrimers, and inorganic nanostructures have all been successfully tested for use in cancer treatment, gene delivery, and the treatment of metabolic and neurological disorders. These developments highlight the enormous potential of nanocarriers to transform patient care by bridging the gap between pharmacological innovation and clinical necessity.[1]

Nanomedicine and nano-delivery systems have recently surfaced as a way to administer drugs locally to specific tumor areas and as a diagnostic tool. Since natural substances are currently being researched for the treatment of cancer as well as a number of other microbial and inflammatory illnesses, nanotechnology is essential to the development of contemporary medication delivery systems. Nanotechnology makes it possible to use nanostructures and other therapeutic agents created at the nanoscale level for nanomedicine. Nanobiotechnology, medication delivery, biosensors, and tissue engineering are all included in the discipline of biomedicine and are heavily impacted by the application of NPs. Nanotechnology has advanced significantly over the last ten years, and potential manufacturing, characterization, and changes of NPs' functional properties are currently being used for biological applications and medical diagnosis. Smaller nanospheres are produced by the atomic and molecular design of materials that make up NPs. Therefore, compared to more extensive materials, nanoscale particles can move freely throughout the human body.[2]

Pharmaceutical research has improved steadily in an effort to improve organ targeting, stability, and drug absorption. Drugs may be found inside the nanocarrier layers or distributed across the nanocarrier matrix. There are numerous ways to deliver them, including as parenteral, nasal, topical, or oral.[3]

A novel approach to biomedical processes from a molecular level is made possible by nanotechnology. Data collecting in nanotechnology is a major usage in biomedical applications due to the recent advancements in both speed and precision. Nanomaterials, which range in size from 1 to 1,000 nm in diameter, have a number of special characteristics that set them apart from bulk materials or fine particles. Certain therapeutic nanomedicine applications in medical biophysics enable the use of nanoscale materials for monitoring, diagnosis, and appropriate prevention of future consequences. Because of the leaky nature of tumor blood arteries, which allows nanoparticles to enter and collect in the tumor due to their small size, nanoparticles can detect cancer. Because of its efficient control and release reservoir, this drug delivery method based on nanoparticles is becoming more and more popular in the field of medical biophysics.[4]

In the meantime, cutting-edge applications in materials science, energy, and medicine rely heavily on nanotechnology, AI's incorporation into nanotechnology is a paradigm shift that provides answers to problems that were previously unsolvable because of the intricacy of the nanoscale.[5]

**Liposomal Drug Delivery and Nanocarriers:** These cutting-edge platforms in contemporary medicine provide effective and tailored drug delivery technologies. A lipid bilayer makes up the vesicular spheres known as liposomes. By incorporating active pharmaceutical chemicals into their framework, they improve medication stability, bioavailability, and therapeutic action. They are the preferred approach for obtaining the best possible therapeutic benefit because of their capacity to provide regulated release and shield medications from enzymatic breakdown.

Smart drug delivery systems that are activated by physiological stimuli for targeted and regulated drug administration at the action site are among the latest advancements in nanocarriers that go beyond traditional liposomes. Nanocarriers have demonstrated enormous promise in overcoming the drawbacks of traditional pharmaceutical products, including systemic toxicity and poor solubility. Liposomal systems are now at the forefront of contemporary pharmaceutical science thanks to the combination of drug delivery with nanotechnology.[6]

**Niosomes Drug Delivery and Nanocarriers -** For intelligent drug delivery applications, niosomes vesicular nanocarriers based on non-ionic surfactants—have become a viable substitute for liposomes. Both hydrophilic and hydrophobic medicinal substances can be encapsulated in these self-assembling bilayer vesicles, which are typically made of non-ionic surfactants and cholesterol. Niosomes allow controlled and targeted drug release, enhance medication stability, and shield encapsulated molecules from premature degradation when compared to traditional drug delivery methods. These developments have increased their potential for treating neurological disorders, inflammatory diseases, infectious diseases, and cancer. Machine learning techniques are being investigated more and more in the field of artificial intelligence in order to forecast encapsulation efficiency, optimize niosomal formulation variables, and expedite the development of tailored nanomedicine. Thus, the combination of niosomal nanotechnology with AI-assisted design is a major step toward precise drug delivery systems with better therapeutic results.[7]

**Glycerosomes Drug Delivery and Nanocarriers -** When compared to traditional liposomes, glycerosomes - modified phospholipid vesicles with high glycerol contents in the aqueous phase - improve membrane flexibility, stability, and drug penetration. Because of their favorable biocompatibility and low toxicity, recent research has shown their potential in treating wound healing, antimicrobial infections, inflammatory skin disorders, and localized cancer therapy. In order to provide site-specific medication delivery, innovations in nanotechnology have also made it possible to functionalize glycerosomes with targeting ligands and stimuli-responsive materials. The creation of glycerosomal formulations is rapidly incorporating artificial intelligence (AI) to simulate drug release profiles, forecast vesicle properties, and optimize important formulation variables. Glycerosome - based nanocarriers and AI-driven formulation design are anticipated to speed up the creation of customized systems, increasing therapeutic efficacy while reducing side effects.[8]

**Hydrogels in Smart Drug Delivery and Nanocarriers -** Hydrogel–nanoparticle hybrid systems, which combine the targeting and transport capabilities of nanocarriers with the sustained release characteristics of hydrogels, have been the subject of recent advancements. In the fields of cancer treatment, wound healing, and the localized treatment of chronic illnesses, these systems have demonstrated significant promise. Additionally, hydrogel formulations are being optimized, swelling behavior is predicted, drug release kinetics are modeled, and the development of customized therapeutic platforms is being accelerated through the use of artificial intelligence (AI) and machine learning approaches. As a result, it is anticipated that AI-assisted hydrogel technologies would have a big impact on smart medication delivery and precision medicine in the future.[9]

## REVIEW OF LITERATURE

***Othman et al. (2026)*** Traditional drug delivery methods have significant drawbacks, including poor therapeutic outcomes, non-specific distribution, and inefficient drug solubility. In order to enable the rational design and optimization of innovative drug delivery, this paper explores how artificial intelligence (AI) techniques can be applied to incorporate nanomaterial platforms, including lipid nanoparticles, polymeric carriers, dendrimers, inorganic nanostructures, peptides, and hybrid systems. This summarizes how artificial intelligence (AI) can change nanomedicine from a field of trial and error to a predictive design that will allow precision medicines to be developed and built to address the most important unmet requirements in disease management.

***Sarhan, O. M. (2026)*** A revolutionary phase in pharmaceutical research has begun with the merging of artificial intelligence (AI) with nanomedicine, enabling advancements in targeted drug delivery, controlled release, and personalized therapies. This review investigates the integration of AI-driven techniques with nanocarrier systems as dendrimers, polymeric nanoparticles, and liposomes. Advanced methods like deep learning, reinforcement learning, and graph neural networks have significantly improved pharmacokinetic predictions by utilizing high-dimensional datasets and predictive modeling. These technologies have issues with algorithmic openness, data standards, and regulatory compliance.

***Shirzad, M. (2025)*** This essay examines the ground-breaking partnership between nanotechnology and artificial intelligence (AI) in the identification and management of breast cancer. Through enhanced imaging and biomarker discovery, AI-based deep learning models in diagnostics can improve diagnosis accuracy and enable accurate, personalized therapy. To improve accessibility and clinical integration, future developments should concentrate on creating multifunctional nanoparticles, adaptable AI algorithms, and scalable, affordable solutions. Therefore, the study highlights the necessity of interdisciplinary cooperation to remove current obstacles and produce innovations to change breast cancer treatments into safer, more effective, and customized approaches.

***Sengar, A. (2025)*** Precision medicine, enhanced bioavailability, and site-specific therapy are made possible by the convergence of nanotechnology, artificial intelligence, and intelligent drug delivery systems, which is transforming modern pharmaceutics. In light of their potential to enhance efficacy, adherence, and drug safety, a few emerging technologies are highlighted, including AI-designed medications, biodegradable drug carriers for delivery, and targeted medication. By enabling site-specific targeting and controlled release, intelligent nanocarriers like liposomes, polymeric nanoparticles, and dendrimers are revolutionizing medication delivery. The future of medicine could be completely changed by new delivery methods and AI-enhanced pharmaceutical development.

***Khalifa, N. E. (2025)*** The pharmaceutical business has undergone a revolution thanks to the incorporation of artificial intelligence (AI) into drug delivery systems, which has made it possible to build more accurate, effective, and customized treatment solutions. This paper examines how AI is revolutionizing important fields like nanotechnology, controlled-release systems, predictive modeling, and customized medicine. With possible integrations with nanotechnology, three-dimensional printing, and the Internet of things, the future of AI in medicine delivery seems bright despite obstacles like data quality, ethical issues, and legal barriers.

***Yadavalli, V. K. (2025)*** Artificial intelligence (AI) algorithms combined with nanoscale production techniques could lead to new developments in nanomanufacturing by speeding up development, streamlining production, cutting costs, boosting quality control, and promoting sustainability. With digital and cyber-physical technologies becoming more and more integrated with "smart" manufacturing and industrial processes, these developments are already taking place. AI and its subfields, such as machine learning (ML), are positioned to be important facilitators of efficiency and innovation in the nano manufacturing sector, which is concentrated on the scalable manufacture of complex (nano)materials, (nano)devices, and biologics.

***Mittal, M. (2025)*** By overcoming the drawbacks of traditional medication delivery techniques, nanotechnology has transformed contemporary therapies. The important developments in drug delivery systems based on nanoparticles are examined in this review article, with an emphasis on how they can improve therapeutic efficacy and overcome drug resistance. Lipid-based, polymer-based, inorganic, and biological nanoparticles provide therapeutic compounds with enhanced solubility, stability, targeted distribution, and controlled release. Furthermore, nanomedicine makes it easier for medications to pass through biological barriers like the blood-brain barrier, creating new therapeutic options for neurological conditions. Combination therapies that target several pathways at once are supported by the capacity to co-encapsulate several therapeutic drugs in nanoparticles, which slows the emergence of resistance.

***Liu, S. (2025)*** AI is revolutionizing healthcare by speeding up disease detection, improving patient care, and facilitating the development of more individualized and potent medications. AI is playing a growing role in the search and delivery of medications as more individuals require more affordable and effective medications. The revolutionary effects of machine learning, deep learning, and large language models on medication discovery are examined in this article. To find the best time and dosage for each patient's treatment, AI evaluates their data. It then develops a customized medication distribution strategy. These new technologies have fewer flaws and are more effective in identifying diseased tissues. Predictive analytics can forecast potential adverse effects and patient reactions.

***Singh, S. (2025)*** One of the difficult tactics proposed to enhance therapy techniques for anxiety disorders, clinic issues of delayed action, side effect-free design, and low patient compliance is the use of nanoparticle-based drug delivery systems. While conventional pharmacological treatments can target particular brain regions and increase drug bioavailability, nanoparticle-mediated controlled release provides improved accuracy and long-lasting impact. The others in this review focus on several types of nanoparticles, such as polymeric-metallic, lipid-based, and responsive nanoparticles, and their application in anxiety drugs. Precision medicine, which focuses on treating patients according to their genetic, environmental, and lifestyle characteristics, is also emphasized.

***Heydari, S. (2024)*** By improving treatment efficiency and lowering adverse effects, nano-based drug delivery systems (DDSs) have proven to be able to overcome the difficulties presented by therapeutic agents. Different nanoparticles (NPs) with distinct properties are used as DDSs, resulting in a variety of applications across various diseases. However, the incorporation of artificial intelligence (AI) technologies has been motivated by the complexity, expense, and time-consuming nature of laboratory procedures, the volume of data, and the difficulties in data analysis. With an emphasis on the therapeutic uses of nano-DDSs, this review paper explores the role of AI in their development. The application of AI in DDSs has the potential to transform therapy optimization and enhance patient care.

## FUNDAMENTALS OF SMART DRUG DELIVERY SYSTEMS

**Conventional vs Smart Drug Delivery Systems -** These systems work well for many therapeutic applications, but they frequently have drawbacks, such as low bioavailability, quick systemic clearance, non-specific distribution, frequent dosage, and unfavorable side effects from exposure to off-target drugs.[20]

On the other hand, are designed to enhance therapeutic precision. By making it possible to forecast formulation properties, optimize carrier design, and simulate drug release behavior using machine learning algorithms, recent developments in artificial intelligence (AI) have further revolutionized smart drug delivery. That can adjust to patient-specific therapeutic needs is made possible by the integration of AI with nanotechnology, which is a major improvement over traditional pharmaceutical method.[21]

**Comparison between Conventional and Smart Drug Delivery Systems**

| **Parameter** | **Conventional Drug Delivery** | **Smart Drug Delivery** | **Key Reference** |
|---|---|---|---|
| Drug release | Immediate predetermined release | Controlled, sustained, and stimuli-responsive release | Peer et al. (2007) |
| Target specificity | Non-specific distribution throughout the body | Site-specific and targeted delivery to diseased tissues | Bae & Park (2011) |
| Drug concentration | Fluctuating plasma drug levels | Maintains therapeutic drug concentration over extended periods | Peer et al. (2007) |
| Bioavailability | Often reduced due to metabolism and poor absorption | Enhanced through nanocarriers and controlled release mechanisms | Peer et al. (2007) |
| Side effects | Systemic drug exposure | Reduced due to localized and targeted drug delivery | Bae & Park (2011) |
| Dosing frequency | Frequent administration is often required | Reduced dosing frequency because of prolonged drug release | Peer et al. (2007) |
| Drug stability | Drugs may undergo rapid degradation | Nanocarriers improve drug protection and stability | Peer et al. (2007) |
| Patient compliance | Lower due to repeated dosing | Improved because of sustained therapeutic action | Peer et al. (2007) |
| Role of Artificial Intelligence | Minimal application | AI supports formulation optimization, carrier design, prediction of drug release, and personalized therapy | Bae & Park (2011) |

**Principles of Smart Drug Delivery Systems -** In contrast to traditional formulations, these systems control medication release in accordance with pathological conditions by utilizing biological or externally applied cues. Changes in pH, enzyme activity are examples of external stimuli. Artificial intelligence (AI) has also been used in recent advancements to improve nanocarrier design using data-driven methods, forecast drug release profiles, and optimize formulation parameters. When taken as a whole, these guidelines seek to improve treatment precision, minimize systemic toxicity, and increase therapeutic efficacy.[24]

**Advantages of Smart Drug Delivery Systems** - These systems extend the duration of circulation inside the body, increase medication bioavailability, and shield labile medicinal molecules from enzymatic breakdown. While smart delivery technologies improve molecular stability and intracellular transport in gene and protein delivery, they also improve the selective accumulation of anticancer medicines at tumor sites in oncology. Pharmaceutical research and development is made more efficient by the incorporation of AI, which also helps with formulation optimization, physicochemical property prediction, and the quick generation of customized nanomedicines.[25]

**Limitations of Smart Drug Delivery Systems -** Smart medication delivery systems still confront a number of technological, scientific, and legal obstacles despite tremendous advancements. Numerous nanocarrier formulations necessitate intricate manufacturing procedures that raise production costs and restrict widespread commercialization. Furthermore, low repeatability and physiological variations between human and animal models frequently make it difficult to translate promising laboratory results into clinical practice. AI can enhance formulation design and process optimization, but its application requires model validation, established experimental procedures, and high-quality datasets.[26]

## NANO PARTICLES IN SMART DRUG DELIVERY

**Types of Nanoparticles in Smart Drug Delivery Systems** - By enhancing therapeutic efficacy, pharmacokinetics, and target specificity, nanoparticles - nanoscale carriers that usually range in size from 1 to 1000 nm - have revolutionized contemporary drug delivery. Nanoparticles utilized in smart medication delivery fall into a number of major types based on their physicochemical properties and composition.[27]

Targeted medication and gene delivery is made easier by dendrimers, which are highly branched macromolecules with several functional surface groups. Imaging, photothermal therapy, and targeted treatment can benefit from the special optical, magnetic, and antibacterial capabilities of metallic nanoparticles, especially those made of gold, silver, and iron oxide. Nanoparticle engineering is a key component of next-generation smart drug delivery systems since the choice of an ideal nanoparticle system on the target tissue, the desired drug-release profile, and the physicochemical characteristics of the therapeutic agent.[28]

**Properties of Nanoparticles in Smart Drug Delivery Systems** - Characteristics, which affect drug loading, circulation time, cellular absorption, and therapeutic efficacy, largely dictate their therapeutic performance in smart drug delivery systems. Nanoparticles with an ideal size range can promote increased accumulation at disease locations while avoiding quick renal clearance. Colloidal stability and interactions with biological membranes are influenced by surface charge (zeta potential); positively charged nanoparticles typically show increased cellular absorption, while neutral or slightly negative particles frequently show extended circulation. The amount of therapeutic agent that can be administered successfully is determined by drug loading capacity and encapsulation efficiency, whereas controlled release properties govern drug availability at the target location over time. When combined, these characteristics allow nanoparticles to enhance therapeutic precision, lessen systemic side effects, and aid in the creation of sophisticated, customized drug delivery systems, for formulation optimization and predictive modeling.[29]

**Biomedical Applications of Nanoparticles in Smart Drug Delivery Systems** - By facilitating targeted, regulated, and customized therapeutic interventions across nanoparticles have greatly broadened the field of smart drug delivery. Through passive and active targeting techniques, nanoparticle-based delivery methods enhance the selective accumulation of chemotherapeutic drugs within tumor tissues in cancer therapy, increasing therapeutic efficacy while lowering systemic toxicity. CRISPR-associated components are among the nucleic acids that nanoparticles shield from enzymatic breakdown and enable effective intracellular delivery in gene therapy. Lipid nanoparticles have shown their clinical relevance in mRNA-based vaccines and have proved especially significant for nucleic acid delivery.

Additionally, nanoparticles are widely used where they improve intracellular drug delivery, overcome biological barriers, and increase the stability of antimicrobial drugs.[30]

Engineered nanoparticles are being studied to neurological illnesses, potentially providing new therapeutic options for conditions including Parkinson's and Alzheimer's. Additionally, cardiovascular medicine, tissue engineering, regenerative medicine, diagnostic imaging, and theragnostic—where they integrate therapeutic and diagnostic capabilities on a single platform—have all seen significant increases in the use of nanoparticles.[31]

## ROLE OF ARTIFICIAL INTELLIGENCE IN NANO PARTICLE BASED DRUG DELIVERY

**AI Techniques in Nanoparticle-Based Drug Delivery** - Data-driven formulation development optimization, nanoparticle behavior prediction, and pharmaceutical research acceleration, as a crucial tool in nanoparticle-based drug delivery. The most often used AI method for determining correlations between formulation variables and crucial quality features, such as particle size, zeta potential, drug loading efficiency, and encapsulation efficiency, is machine learning (ML). Using experimental datasets, supervised learning methods used to forecast nanoparticle properties and optimize formulation parameters.[32]

Furthermore, a promising method for the sequential optimization of formulation processes and adaptive drug delivery strategies is reinforcement learning (RL). Additionally, virtual screening, and predictive simulations that speed up nanoparticle creation and lower experimental costs. Explainable AI (XAI) has garnered attention in recent times due to its potential to enhance the interpretability of prediction models, which can lead to regulatory acceptability and clinical translation. When combined, these AI methods improve formulation accuracy, shorten development times, and facilitate the development of intelligent nanoparticle systems that can provide tailored treatments with increased safety and therapeutic efficacy.[33]

**AI-Assisted Nanoparticle Design for Smart Drug Delivery -** By facilitating the logical creation of nanocarriers with ideal physicochemical and biological characteristics, artificial intelligence (AI) has revolutionized the design of nanoparticles. Traditional nanoparticle formulation frequently depends on labour-intensive, time-consuming, and costly trial-and-error experimentation. By examining big experimental datasets to find correlations between formulation variables and nanoparticle performance, AI-driven computational methods get over these restrictions. By choosing appropriate biomaterials, polymers, lipids, surfactants, and formulation conditions that optimize therapeutic effectiveness while reducing the number of experimental iterations, these predictive models help researchers. The creation of nanoparticles with improved stability, biocompatibility, cellular uptake, and tissue-specific targeting is made easier by deep learning.[34]

Additionally, computational molecular design and generative AI are becoming potent tools for creating innovative nanocarrier structures suited to certain illnesses and patient groups. AI greatly speeds up the development of nanoparticles, lowers research costs, and advances precision medicine through safer, more effective, and customized smart drug delivery systems by fusing predictive analytics with experimental nanotechnology.[35]

**AI-Assisted Drug Loading Optimization in Nanoparticle-Based Drug Delivery** - Because it establishes the amount of therapeutic substance contained within a nanocarrier and directly affects therapeutic efficacy, dose frequency, and formulation stability, drug loading is an essential parameter in nanoparticle-based drug delivery systems. Complex nonlinear correlations between formulation factors and outcomes, including drug loading capacity, encapsulation efficiency, particle size, and drug release behavior, are identified using these computational models. In order to expedite the formulation of nanoparticles and enhance loading performance for small molecules, proteins, peptides, and nucleic acid therapies, recent research has also combined AI with high-throughput screening and molecular simulation tools. Therefore, AI-driven drug loading optimization is a crucial tactic for creating effective, repeatable, and customized drug delivery systems based on nanoparticles that satisfy contemporary pharmaceutical and clinical needs.[36]

**AI-Based Drug Release Prediction in Nanoparticle Drug Delivery Systems** - Since drug release profiles have a direct impact on patient safety, dosage frequency, and therapeutic efficacy, accurate prediction of these profiles is crucial for the development of nanoparticle-based drug delivery systems. Traditional methods rely on lengthy, which are frequently costly, time-consuming, and challenging to optimize. By combining cutting-edge with experimental formulation data, artificial intelligence (AI) has become a potent computational tool for forecasting drug release behavior. Nonlinear relationships between nanoparticle composition, particle size, polymer properties, encapsulation efficiency, and drug release kinetics can be found using supervised learning models.[37]

By examining multidimensional datasets produced from pharmaceutical formulations and characterisation investigations, deep learning algorithms significantly enhance predictive performance. By estimating release profiles under various physiological situations, AI-driven models can improve formulation accuracy and eliminate the need for repeating laboratory experiments. Additionally, by determining formulation parameters that produce desirable release characteristics, computer modeling aids in the design of sustained and stimuli-responsive drug delivery systems. Therefore, combining AI with computational pharmaceutics speeds up the development of nanoparticles, improves the reproducibility of formulations, and supports personalized medicine by optimizing controlled drug delivery systems predictively.[38]

**AI-Based Toxicity Prediction in Nanoparticle Drug Delivery Systems** - Because the physicochemical properties of nanoparticles can affect their interactions with biological tissues, immunological responses, and long-term biocompatibility, safety assessment is an essential step in the development of drug delivery systems based on nanoparticles. Extensive in vitro, in vivo, and clinical studies are necessary for conventional toxicity evaluation; these studies are frequently and labour-intensive. By combining physicochemical characteristics with biological and toxicological facts, artificial intelligence (AI) has become a useful method for predicting the toxicity of nanoparticles. Gradient boosting, and artificial neural networks are examples of machine learning algorithms that can recognize intricate connections between toxicological results and nanoparticle.[39]

Early detection of potentially dangerous nanomaterials prior to experimental validation is made possible by AI-based predictive models, which save development costs and minimize needless animal testing. Moreover, deep learning techniques can enhance the accuracy of toxicity prediction by analyzing imaging datasets, cellular response profiles, and high-dimensional omics data. These computational techniques also facilitate the creation of safe-by-design nanoparticles, which enable scientists to maximize the composition of nanocarriers while preserving their therapeutic efficacy. By enhancing safety and clinical translation, AI algorithms are anticipated to play a more significant role in regulatory decision-making, nanomedicine development, and precision drug delivery as they continue to develop with larger and more standardized toxicological datasets.[40]

**AI-Driven Personalized Medicine in Nanoparticle-Based Drug Delivery** - By taking into account molecular and clinical characteristics, personalized medicine seeks to give the correct therapeutic intervention to the right patient at the right dose and timing. By enabling patient-specific therapeutic approaches, the combination of artificial intelligence (AI) with nanoparticle-based medication delivery has greatly advanced this idea. In order to find illness biomarkers, forecast treatment outcomes, and suggest customized treatment plans, AI algorithms examine massive datasets produced by genomes, proteomics, metabolomics, medical imaging, and electronic health records. The rational design of nanoparticles with optimal size, surface chemistry, drug loading capacity, and targeting ligands suited to particular patient populations is made easier by these insights.[41]

Additionally, pharmacokinetics, drug release behavior, and nanoparticle biodistribution are predicted by machine learning and deep learning models, increasing treatment precision while reducing side effects. AI-assisted nanoparticle systems in oncology allow for customized treatment by choosing the best nanocarrier formulation based on genetic biomarkers and tumor features.[42]

Similar approaches are being investigated for inflammatory ailments, cardiovascular diseases, and neurological disorders, where patient heterogeneity greatly affects treatment results. Additionally, by combining real-time clinical data with predictive analytics, AI facilitates ongoing treatment optimization by enabling flexible changes to medication dosage and delivery schedules. Therefore, the combination of AI, nanotechnology, and precision medicine offers a revolutionary way to create intelligent drug delivery systems that optimize therapeutic efficacy, enhance patient safety, and hasten the shift to personalized healthcare.[43]

**Advantages and Limitations of Major Nanoparticles Used in Smart Drug Delivery**

| Nanoparticle Type | Major Advantages | Major Limitations | Representative Applications | Key Reference |
|---|---|---|---|---|
| **Polymeric Nanoparticles** | Controlled drug release; biodegradable; versatile surface modification | Complex manufacturing; possible polymer degradation issues | Targeted drug delivery, protein and peptide delivery | Danhier et al. (2012) |
| **Solid Lipid Nanoparticles (SLNs)** | Good stability; protects labile drugs; scalable production | Limited drug loading; lipid crystallization | Oral, topical and parenteral drug delivery | Müller, Radtke, & Wissing (2002) |
| **Nanostructured Lipid Carriers (NLCs)** | Higher drug loading than SLNs; improved storage stability | Formulation optimization is challenging | Controlled and sustained drug delivery | Müller et al. (2011) |
| **Dendrimers** | High loading capacity; precise architecture; multiple functional groups | Cytotoxicity at high generations; expensive synthesis | Gene delivery, anticancer therapy | Tomalia & Frechet (2002) |
| **Gold Nanoparticles** | Excellent optical properties; easy surface functionalization | Non-biodegradable; long-term accumulation concerns | Imaging, photothermal therapy | Dykman & Khlebtsov (2012) |
| **Silver Nanoparticles** | Broad-spectrum antimicrobial activity | Potential cytotoxicity and oxidative stress | Antimicrobial coatings, wound healing | Rai et al. (2014) |
| **Mesoporous Silica Nanoparticles** | Large surface area; high drug loading; tunable pore size | Slow biodegradation; possible inflammatory response | Controlled drug delivery, imaging | Slowing et al. (2008) |
| **Magnetic Nanoparticles** | Magnetic targeting; MRI contrast enhancement | Oxidation and aggregation may reduce performance | Magnetic targeting, hyperthermia | Pankhurst et al. (2003) |
| **Carbon-Based Nanomaterials** | High surface area; excellent mechanical strength | Concerns regarding long-term biocompatibility and toxicity | Biosensors, drug delivery, tissue engineering | Bianco et al. (2005) |

## CHALLENGES AND FUTURE DIRECTIONS

**Neurological Disorders: Clinical Applications of AI-Assisted Nanoparticle Drug Delivery** - Because the blood–brain barrier (BBB) prevents most medications from reaching the central nervous system, neurological conditions like glioblastoma, epilepsy, and stroke pose significant treatment hurdles. Lipid nanoparticles, polymeric nanoparticles, and dendrimers are examples of nanoparticle-based drug delivery methods that have shown great promise in overcoming this obstacle by boosting drug transport, increasing bioavailability, and facilitating targeted administration to brain tissues. By combining clinical, imaging, and molecular data to optimize nanoparticle design, estimate BBB permeability, model drug release patterns, and customize treatment approaches, artificial intelligence (AI) further improves these systems. Additionally, machine learning algorithms enhance therapeutic decision-making and make it easier to identify disease-specific biomarkers. A promising strategy for creating safer, more effective, and patient-specific treatments for neurological conditions while lowering systemic toxicity and enhancing clinical results is the combination of AI and nanoparticle technology.[53]

**Infectious Diseases: Clinical Applications of AI-Assisted Nanoparticle Drug Delivery -** Due to restricted targeted delivery, poor drug absorption, and antibiotic resistance, infectious illnesses continue to be major global health issues.

By improving medication stability, controlled release, and targeted distribution to infected tissues, nanoparticle have become successful platforms for boosting the therapeutic efficacy of antimicrobial medicines. Treatment of bacterial, viral, fungal, and parasitic infections has shown great promise with lipid nanoparticles, polymeric nanoparticles, metallic nanoparticles, and liposomal formulations. By evaluating microbial genomic data, forecasting antibiotic resistance patterns, refining nanoparticle formulations, and determining patient-specific treatment approaches, artificial intelligence (AI) enhances these applications even more. Additionally, machine learning algorithms can forecast the new antimicrobial nanocarriers and expedite their discovery. Therefore, combining AI and nanotechnology offers a novel approach to fighting infectious diseases while enhancing treatment accuracy, reducing systemic toxicity, and assisting in the creation of next-generation antimicrobial treatments.[54]

**Gene Therapy: Clinical Applications of AI-Assisted Nanoparticle Drug Delivery** - By introducing therapeutic and small interfering RNA into target cells, gene therapy has become a promising approach for treating hereditary, infectious, and cancerous disorders. Lipid nanoparticles (LNPs), polymeric nanoparticles, and lipid–polymer hybrid nanoparticles are examples of nanoparticle-based delivery systems that minimize immunogenicity while protecting nucleic acids from enzymatic breakdown, improving cellular absorption, and increasing gene transfection effectiveness. By improving nanoparticle composition, forecasting transfection effectiveness, simulating biodistribution, and determining the best delivery methods for particular genetic targets, artificial intelligence (AI) promotes gene therapy. By combining genomic and pharmacological data, machine learning algorithms also make it easier to create customized gene delivery systems. The development of safe, effective, and precise gene treatments for a variety of therapeutic applications is being accelerated by the integration of AI with nanoparticle technologies.[55]

**Vaccine Delivery: Clinical Applications of AI-Assisted Nanoparticle Drug Delivery** - By increasing antigen stability, boosting immune responses, and facilitating targeted administration to antigen-presenting cells, nanoparticle-based vaccine delivery technologies have revolutionized modern immunization. Because they prevent vaccine components from degrading and facilitate effective cellular uptake, lipid nanoparticles (LNPs), polymeric nanoparticles, virus-like particles, as vaccine carriers. The importance of lipid nanoparticles in the safe and efficient delivery of nucleic acids has been brought to light by the clinical success of mRNA vaccines. By discovering protective antigens, improving the composition of nanoparticles, forecasting immune responses, and speeding up formulation development with machine learning algorithms, artificial intelligence (AI) significantly advances the development of vaccines. By combining genomic and immunological data, AI also facilitates customized vaccine creation, enhancing vaccination safety and efficacy. The development of next-generation vaccines against infectious diseases and new threats to global health is anticipated to be accelerated by the integration of AI with nanoparticle technology.[56]

## HOW AI BASED NANO PARTICLES ACT IN DIFFERENT DISEASES

By tailoring the properties of nanocarriers to the biological features of certain diseases, artificial intelligence (AI) improves medicine delivery using nanoparticles. In order to forecast the ideal nanoparticle composition, surface ligands, particle size, and drug-release kinetics for targeted therapy, AI algorithms combine genetic, proteomic, imaging, and pharmacological datasets.[57]

AI makes it easier to create nanoparticles that enhance intracellular medication delivery and specifically accumulate inside malignancies. AI predicts the permeability of the blood–brain barrier for neurological illnesses and directs the creation of nanocarriers that can deliver medications into the central nervous system. AI finds pathogen-specific biomarkers and patterns of antibiotic resistance in infectious disorders, allowing for the creation of nanoparticles with improved antimicrobial efficiency. AI minimizes degradation and off-target effects while optimizing lipid and polymeric nanoparticles for effective delivery of DNA, mRNA, and siRNA during gene therapy.[58]

Similar to this, AI aids in the selection of antigens, forecasts immunological reactions, and enhances nanoparticle formulations to increase the stability and immunogenicity of vaccines. When combined, AI-driven nanoparticle systems improve clinical outcomes and speed up precision medicine by enabling disease-specific targeting, controlled drug release, decreased systemic toxicity, and customized therapeutic interventions.[59]

## CHALLENGES AND FUTURE DIRECTIONS

**Regulatory Challenges** - The lack of standardized regulatory frameworks impedes the clinical translation of AI-enabled nanoparticle therapies. When assessing hybrid technologies that integrate nanomedicine and artificial intelligence, current pharmacological rules are frequently insufficient. Inconsistent characterisation techniques, a dearth of long-term safety data, a lack of a uniform quality evaluation, and uncertainty about the validation of AI models are some of the difficulties. Assessing constantly changing machine-learning algorithms employed in clinical decision assistance and formulation improvement presents challenges for regulatory bodies as well. To create internationally recognized standards for safety evaluation, efficacy assessment, transparency, and lifecycle monitoring of AI-assisted nanomedicines, international cooperation between regulatory bodies, researchers, and industry is crucial.[60]

**Ethical Challenges -** Important ethical questions about patient privacy, informed consent, algorithmic bias, transparency, and fair access to healthcare are brought up by the incorporation of AI into nanoparticle-based drug delivery. Large biological datasets are essential to AI systems, necessitating robust data governance and patient privacy protection. Unfair treatment suggestions for various populations may arise from biased or non-representative datasets. Furthermore, clinical decision-making and accountability are complicated by the restricted interpretability of complex AI models. Therefore, to enable responsible development and fair clinical acceptance of AI-assisted nanomedicine, ethical implementation necessitates clear algorithms, explainable AI, strict data protection measures, and globally recognized ethical principles.[61]

**Research Gaps** - The successful clinical translation of AI-assisted nanoparticle medication delivery is still limited by a number of research gaps, despite the technology's impressive advancements. The majority of artificial intelligence models are less reproducible and generalizable across various disease models and patient groups since they are trained on relatively short, heterogeneous, and non-standardized datasets. Additionally, the creation of reliable predictive models is hampered by the inadequate integration of multi-omics, pharmacokinetic, toxicological, and clinical datasets.

Widespread adoption is further hampered by the lack of uniform regulatory frameworks, insufficient benchmarking standards, and little prospective clinical validation. To enhance model dependability, regulatory acceptance, and the development of personalized nanomedicine, future research should give priority to the development of standardized, FAIR-compliant datasets, explainable AI (XAI) models, multicenter validation studies, and interdisciplinary collaborations.[62]

## CONCLUSION

A revolutionary approach to enhancing the accuracy, effectiveness, and security of contemporary treatments nanoparticle-based smart medication delivery. By forecasting crucial formulation parameters, such as particle size, surface properties, drug loading, release kinetics, biodistribution, and toxicity, AI-driven computational techniques make it possible to rationally design and optimize nanocarriers. In addition to enhancing bioavailability, reducing off-target effects, and facilitating regulated drug release, nanoparticles also improve the targeted delivery of medicinal substances.

These developments have shown such as gene therapy, cancer treatment, neurological conditions, infectious diseases, and vaccine administration. Notwithstanding these successes, a number of obstacles still exist, such as the scarcity of standardized datasets, the lack of clinical validation, regulatory ambiguity, ethical issues with data privacy and algorithm transparency, and challenges with large-scale production and commercialization.

It will take interdisciplinary cooperation between pharmaceutical experts, physicians, materials scientists, computational researchers, and regulatory bodies to overcome these obstacles. To increase the dependability and practical translation of AI-assisted nanotherapeutics, future research should concentrate on the creation of explainable AI models, standardized nanomedicine databases, multimodal data integration, and prospective clinical trials.

All things considered providing previously unheard-of chances to advance personalized medicine, enhance therapeutic outcomes, and aid in the creation of safer, more efficient, and patient-centered healthcare solutions. It is anticipated that ongoing innovation in this multidisciplinary area will be crucial to the development of intelligent drug delivery systems and precision medicine in the future.

## REFERENCES


1. Han, Y., Kim, D. H., & Pack, S. P., Nanomaterials in drug delivery: Leveraging artificial intelligence and big data for predictive design. *International Journal of Molecular Sciences,* 2025; *26*(22): 11121.
2. Das, K. P., Nanoparticles and convergence of artificial intelligence for targeted drug delivery for cancer therapy: Current progress and challenges. *Frontiers in Medical Technology,* 2023; *4*: 1067144.

3. Alshawwa, S. Z., Kassem, A. A., Farid, R. M., Mostafa, S. K., & Labib, G. S., Nanocarrier drug delivery systems: Characterization, limitations, future perspectives, and implementation of artificial intelligence. *Pharmaceutics*, 2022; *14*(4): 883.
4. Moore, J. A., & Chow, J. C., Recent progress and applications of gold nanotechnology in medical biophysics using artificial intelligence and mathematical modeling. *Nano Express*, 2021; *2*(2): 022001.
5. Elabiad, S., *Artificial intelligence in nanotechnology: Transforming innovation at the atomic scale* (SSRN Scholarly, 2025; Paper No. 5108426). SSRN. https://ssrn.com/abstract=5108426
6. Sengar, A., *The role of liposomal drug delivery in modern medicine and the expanding potential of nanocarriers*, 2025.
7. Moghassemi, S., & Hadjizadeh, A., Nano-niosomes as nanoscale drug delivery systems: An illustrated review. *Journal of Controlled Release*, 2014; *185*: 22–36. https://doi.org/10.1016/j.jconrel.2014.04.015
8. Manca, M. L., Castangia, I., Zaru, M., Nacher, A., Valenti, D., Fernandez-Busquets, X., Fadda, A. M., & Manconi, M., Development of curcumin-loaded glycerosomes for the management of inflammatory skin diseases. *International Journal of Pharmaceutics*, 2014; *478*(1): 226–233. https://doi.org/10.1016/j.ijpharm.2014.11.017
9. Buwalda, S. J., Boere, K. W. M., Dijkstra, P. J., Feijen, J., Vermonden, T., & Hennink, W. E., Hydrogels in a historical perspective: From simple networks to smart materials. *Journal of Controlled Release*, 2014; *190*: 254–273. https://doi.org/10.1016/j.jconrel.2014.03.052
10. Othman, H. O., Ali, D. S., & Hassan, R. O., AI-nanotechnology synergy: Revolutionizing precision drug delivery systems: A comprehensive review. *Analytical Chemistry Letters*, 2026; *16*(2): 95–115.
11. Sarhan, O. M., Gebril, M. I., & Elsegaie, D., Artificial intelligence-enabled nanomedicine: Enhancing drug design and predictive modeling in pharmaceutics. *Journal of Pharmacy and Pharmacology*, 2026; *78*(3): rgaf113.
12. Shirzad, M., Shaban, M., Mohammadzadeh, V., Rahdar, A., Fathi-Karkan, S., Hoseini, Z. S., ... Aboudzadeh, M. A., Artificial intelligence-assisted design of nanomedicines for breast cancer diagnosis and therapy: Advances, challenges, and future directions. *BioNanoScience*, 2025; *15*(3): 354.
13. Sengar, A., Smart drug delivery: AI, nanotech, and future innovations, 2025.
14. Khalifa, N. E., The role of artificial intelligence in the development of modern drug delivery systems. Asian Journal of Pharmaceutical Research and Health Care, 2025; 17(2): 117–123.
15. Yadavalli, V. K., The convergence of nanomanufacturing and artificial intelligence: Trends and future directions. Nanotechnology, 2025; 36(22): 222001. https://doi.org/10.1088/1361-6528/adbf44
16. Mittal, M., Juneja, S., Pandey, N., & Mittal, R., Nanoparticle-based drug delivery systems: Current advances and future directions. Current Drug Targets. Advance online publication, 2025.
17. Liu, S., Revolutionizing healthcare: The role of artificial intelligence in drug discovery and delivery. Journal of Angiotherapy, 2025; 9(1): 1–16.
18. Heydari, S., Masoumi, N., Esmaeeli, E., Ayyoubzadeh, S. M., Ghorbani-Bidkorpeh, F., & Ahmadi, M., Artificial intelligence in nanotechnology for treatment of diseases. Journal of Drug Targeting, 2024; 32(10): 1247–1266. https://doi.org/10.1080/1061186X.2024.2355789
19. Singh, S., Singh, A., & Sharma, S., Precision nanomedicine for anxiety: Challenges, opportunities, and future directions in targeted drug delivery. Journal of Food and Drug Analysis, 2025; 33(3): 241.
20. Allen, T. M., & Cullis, P. R., Drug delivery systems: Entering the mainstream. Science, 2004; 303(5665): 1818–1822. https://doi.org/10.1126/science.1095833

21. Torchilin, V. P., Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. Nature Reviews Drug Discovery, 2014; 13(11): 813–827. https://doi.org/10.1038/nrd4333
22. Bae, Y. H., & Park, K., Targeted drug delivery to tumors: Myths, reality and possibility. Journal of Controlled Release, 2011; 153(3): 198–205. https://doi.org/10.1016/j.jconrel.2011.06.001
23. Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R., Nanocarriers as an emerging platform for cancer therapy. Nature Nanotechnology, 2007; 2(12): 751–760. https://doi.org/10.1038/nnano.2007.387
24. Langer, R., Drug delivery and targeting. Nature, 1998; 392(6679 Suppl.): 5–10. https://doi.org/10.1038/34145
25. Anselmo, A. C., & Mitragotri, S., Nanoparticles in the clinic: An update. Bioengineering & Translational Medicine, 2019; 4(3): e10143. https://doi.org/10.1002/btm2.10143
26. Hare, J. I., Lammers, T., Ashford, M. B., Puri, S., Storm, G., & Barry, S. T., Challenges and strategies in anti-cancer nanomedicine development. Advanced Drug Delivery Reviews, 2017; 108: 25–38. https://doi.org/10.1016/j.addr.2016.09.006
27. Mitragotri, S., Lammers, T., Bae, Y. H., Schwendeman, S., De Smedt, S. C., Leroux, J.-C., et al., Drug delivery research for the future: Expanding the nano horizons and beyond. Nature Reviews Drug Discovery, 2021; 20(2): 101–124. https://doi.org/10.1038/s41573-020-0091-8
28. Blanco, E., Shen, H., & Ferrari, M., Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nature Biotechnology, 2015; 33(9): 941–951. https://doi.org/10.1038/nbt.3330
29. Danhier, F., Feron, O., & Preat, V., To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. Journal of Controlled Release, 2010; 148(2): 135–146. https://doi.org/10.1016/j.jconrel.2010.08.027
30. Hou, X., Zaks, T., Langer, R., & Dong, Y., Lipid nanoparticles for mRNA delivery. Nature Reviews Materials, 2021; 6(12): 1078–1094. https://doi.org/10.1038/s41578-021-00358-0
31. Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C., Cancer nanomedicine: Progress, challenges, and opportunities. Nature Reviews Cancer, 2017; 17(1): 20–37. https://doi.org/10.1038/nrc.2016.108
32. Paul, D., Sanap, G., Shenoy, S., Kalyane, D., Kalia, K., & Tekade, R. K., Artificial intelligence in drug discovery and development. Drug Discovery Today, 2021; 26(1): 80–93. https://doi.org/10.1016/j.drudis.2020.10.010
33. Vamathevan, J., Clark, D., Czodrowski, P., Dunham, I., Ferran, E., Lee, G., Li, B., Madabhushi, A., Shah, P., Spitzer, M., & Zhao, S., Applications of machine learning in drug discovery and development. Nature Reviews Drug Discovery, 2019; 18(6): 463–477. https://doi.org/10.1038/s41573-019-0024-5
34. Jimenez-Luna, J., Grisoni, F., Weskamp, N., & Schneider, G., Artificial intelligence in drug discovery: Recent advances and future perspectives. Expert Opinion on Drug Discovery, 2021; 16(9): 949–959. https://doi.org/10.1080/17460441.2021.1909567
35. Schneider, G., Lübkemann, C., et al., Rethinking drug design in the artificial intelligence era. Nature Reviews Drug Discovery, 2020; 19(5): 353–364. https://doi.org/10.1038/s41573-019-0050-3
36. Mak, K. K., & Pichika, M. R., Artificial intelligence in drug development: Present status and future prospects. Drug Discovery Today, 2019; 24(3): 773–780. https://doi.org/10.1016/j.drudis.2018.11.014
37. He, S., de la Rosa, V. R., & Buehler, M. J., Artificial intelligence for materials and drug delivery system design. Nature Reviews Materials, 2024; 9(2): 102–120. https://doi.org/10.1038/s41578-023-00634-8

38. Wang, Z., Lin, Y., & Xu, B., Machine learning in pharmaceutical formulation development and drug release prediction. Advanced Drug Delivery Reviews, 2023; 198: 114919. https://doi.org/10.1016/j.addr.2023.114919
39. Furxhi, I., Murphy, F., Mullins, M., Arvanitis, A., & Poland, C. A., Machine learning prediction of nanoparticle in vitro toxicity: A systematic review. Nanotoxicology, 2020; 14(2): 140–171. https://doi.org/10.1080/17435390.2019.1680221
40. Luechtefeld, T., Maertens, A., Russo, D. P., Rovida, C., Zhu, H., & Hartung, T., Global analysis of publicly available safety data for predictive toxicology using machine learning. ALTEX, 2018; 35(1): 95–108. https://doi.org/10.14573/altex.1710171
41. Xu, C., Jackson, S. A., et al., Machine learning and complex biological data in precision medicine. Genomics, Proteomics & Bioinformatics, 2019; 17(2): 126–135. https://doi.org/10.1016/j.gpb.2019.01.004
42. Johnson, K. B., Wei, W. Q., Weeraratne, D., Frisse, M. E., Misulis, K., Rhee, K., Zhao, J., & Snowdon, J. L., Precision medicine, AI, and the future of personalized healthcare. Clinical and Translational Science, 2021; 14(1): 86–93. https://doi.org/10.1111/cts.12884
43. Topol, E. J., High-performance medicine: The convergence of human and artificial intelligence. Nature Medicine, 2019; 25(1): 44–56. https://doi.org/10.1038/s41591-018-0300-7
44. Danhier, F., Ansorena, E., Silva, J. M., Coco, R., Le Breton, A., & Préat, V., PLGA-based nanoparticles: An overview of biomedical applications. Journal of Controlled Release, 2012; 161(2): 505–522. https://doi.org/10.1016/j.jconrel.2012.01.043
45. Muller, R. H., Radtke, M., & Wissing, S. A., Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Advanced Drug Delivery Reviews, 2002; 54(Suppl. 1): S131–S155. https://doi.org/10.1016/S0169-409X(02)00118-7
46. Muller, R. H., Staufenbiel, S., & Keck, C. M., Lipid nanoparticles (SLN & NLC): State of the art and future perspectives. *European Journal of Pharmaceutics and Biopharmaceutics*, 2011.
47. Tomalia, D. A., & Fréchet, J. M. J., Discovery of dendrimers and dendritic polymers: A brief historical perspective. *Journal of Polymer Science Part A: Polymer Chemistry*, 2002; *40*(16): 2719–2728. https://doi.org/10.1002/pola.10301
48. Dykman, L. A., & Khlebtsov, N. G., Gold nanoparticles in biomedical applications: Recent advances and perspectives. *Chemical Society Reviews*, 2012; *41*(6): 2256–2282. https://doi.org/10.1039/C1CS15166E
49. Rai, M., Deshmukh, S. D., Ingle, A. P., & Gade, A. K., Silver nanoparticles: The powerful nanoweapon against multidrug-resistant bacteria. *Journal of Applied Microbiology*, 2012; *112*(5): 841–852. https://doi.org/10.1111/j.1365-2672.2012.05253.x
50. Slowing, I. I., Vivero-Escoto, J. L., Wu, C. W., & Lin, V. S. Y., Mesoporous silica nanoparticles as controlled release drug delivery systems. *Advanced Drug Delivery Reviews*, 2008; *60*(11): 1278–1288. https://doi.org/10.1016/j.addr.2008.03.012
51. Pankhurst, Q. A., Connolly, J., Jones, S. K., & Dobson, J., Applications of magnetic nanoparticles in biomedicine. *Journal of Physics D: Applied Physics*, 2003; *36*(13): R167–R181. https://doi.org/10.1088/0022-3727/36/13/201
52. Bianco, A., Kostarelos, K., & Prato, M., Applications of carbon nanotubes in drug delivery. *Current Opinion in Chemical Biology*, 2005; *9*(6): 674–679. https://doi.org/10.1016/j.cbpa.2005.10.005

53. Saraiva, C., Praça, C., Ferreira, R., Santos, T., Ferreira, L., & Bernardino, L., Nanoparticle-mediated brain drug delivery: Overcoming the blood–brain barrier to treat neurodegenerative diseases. *Journal of Controlled Release*, 2016; *235*: 34–47. https://doi.org/10.1016/j.jconrel.2016.05.044
54. Pelgrift, R. Y., & Friedman, A. J., Nanotechnology as a therapeutic tool to combat microbial resistance. *Advanced Drug Delivery Reviews*, 2013; *65*(13–14): 1803–1815. https://doi.org/10.1016/j.addr.2013.07.011
55. Cullis, P. R., & Hope, M. J., Lipid nanoparticle systems for enabling gene therapies. *Molecular Therapy*, 2017; *25*(7): 1467–1475. https://doi.org/10.1016/j.ymthe.2017.03.013
56. Irvine, D. J., Aung, A., & Silva, M., Controlling timing and location in vaccines. *Advanced Drug Delivery Reviews*, 2020; *158*: 91–115. https://doi.org/10.1016/j.addr.2020.06.019
57. Mazumdar, H., Khondakar, K. R., Das, S., Halder, A., & Kaushik, A., Artificial intelligence for personalized nanomedicine: From material selection to patient outcomes. *Expert Opinion on Therapeutic Patents*, 2024. https://doi.org/10.1080/17425247.2024.2440618
58. Habeeb, M., You, H. W., Umapathi, M., Ravikumar, K. K., Hariyadi, & Mishra, S., Strategies of artificial intelligence tools in the domain of nanomedicine. *Journal of Drug Delivery Science and Technology*, 2024; *91*: 105157. https://doi.org/10.1016/j.jddst.2023.105157
59. Das, K. P., & Chandra, J., Nanoparticles and convergence of artificial intelligence for targeted drug delivery for cancer therapy: Current progress and challenges. *Frontiers in Medical Technology*, 2023; *4*: 1067144. https://doi.org/10.3389/fmedt.2022.1067144
60. Mangla, B., et al., Regulating nanomedicines: Challenges, opportunities, and the path forward. *Nanomedicine*, 2025. https://doi.org/10.1080/17435889.2025.2533107
61. Wasti, S., et al., Ethical and legal challenges in nanomedical innovations: A scoping review. *Frontiers in Genetics*, 2023; *14*: 1163392. https://doi.org/10.3389/fgene.2023.1163392
62. Chou, W.-C., Canchola, A., Zhang, F., & Lin, Z., Machine learning and artificial intelligence in nanomedicine. *WIREs Nanomedicine and Nanobiotechnology*, 2025; *17*(4): e70027. https://doi.org/10.1002/wnan.70027